Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

PURPOSE: The subcutaneous (SC) administration of trastuzumab is highly preferred by patients. At home, administration of trastuzumab SC might further improve patient benefit. The aims of the BELIS study are to evaluate the safety and tolerability of trastuzumab SC when administered at home by a heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Denys, Hannelore, Martinez-Mena, Corina L., Martens, Marc T., D’Hondt, Randal G., Graas, Marie-Pascale L., Evron, Ella, Fried, Georgeta, Ben-Baruch, Noa E., Vulsteke, Christof, Van Steenberghe, Mona M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182624/
https://www.ncbi.nlm.nih.gov/pubmed/32240454
http://dx.doi.org/10.1007/s10549-020-05604-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182624/
https://www.ncbi.nlm.nih.gov/pubmed/32240454
http://dx.doi.org/10.1007/s10549-020-05604-7

Ejemplares similares